Published in J Acquir Immune Defic Syndr on August 15, 2013
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr (2016) 0.95
Models for predicting effective HIV chemoprevention in women. J Acquir Immune Defic Syndr (2015) 0.87
MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model. Antimicrob Agents Chemother (2015) 0.86
Differential profiles of immune mediators and in vitro HIV infectivity between endocervical and vaginal secretions from women with Chlamydia trachomatis infection: a pilot study. J Reprod Immunol (2013) 0.85
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology (2013) 0.84
MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection. Antimicrob Agents Chemother (2014) 0.84
Expression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque. AIDS Res Hum Retroviruses (2014) 0.83
Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial. Medicine (Baltimore) (2016) 0.77
Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women. AIDS Res Hum Retroviruses (2016) 0.77
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine (2016) 0.76
Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Clin Infect Dis (2015) 0.75
ANALYTICAL ADVANCES IN THE EX VIVO CHALLENGE EFFICACY ASSAY. AIDS Res Hum Retroviruses (2016) 0.75
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Freezing of living cells: mechanisms and implications. Am J Physiol (1984) 4.05
Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol (2000) 3.68
Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS (2000) 2.99
Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod (2005) 2.48
A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis (2005) 2.26
Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother (2007) 2.22
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 2.01
Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS (2006) 1.88
First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One (2011) 1.84
Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol (2011) 1.67
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses (2012) 1.67
Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis (2002) 1.25
Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses (2012) 1.23
Multisite comparison of anti-human immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J Clin Microbiol (2009) 1.23
Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res Hum Retroviruses (2006) 1.17
Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. AIDS Res Hum Retroviruses (2012) 1.14
Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet Gynecol (2003) 1.10
Nonreproducibility of "snap-frozen" rectal biopsies for later use in ex vivo explant infectibility studies. AIDS Res Hum Retroviruses (2012) 0.90
In vitro effect of oral antiseptics on human immunodeficiency virus-1 and herpes simplex virus type 1. J Clin Periodontol (2001) 0.80
Role of anesthetic agents on cardiac and immune systems. Shock (2011) 0.78
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis (2003) 3.24
Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis (2003) 3.20
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol (2006) 2.56
Absence of ageism in access to critical care: a cross-sectional study. Age Ageing (2003) 2.14
Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 2.12
A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2008) 2.09
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94
Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol (2002) 1.85
Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol (2002) 1.73
Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. J Infect Dis (2005) 1.72
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect (2007) 1.70
Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis (2003) 1.70
RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses (2012) 1.67
Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol (2004) 1.65
Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis (2004) 1.65
Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol (2007) 1.63
Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis (2005) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis (2002) 1.54
Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception (2006) 1.52
Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis (2003) 1.44
Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis (2003) 1.38
In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother (2006) 1.37
The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2006) 1.35
Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother (2012) 1.34
Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr (2015) 1.32
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by strand displacement amplification and relevance of the amplification control for use with vaginal swab specimens. J Clin Microbiol (2003) 1.26
Why women douche and why they may or may not stop. Sex Transm Dis (2003) 1.26
Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol (2004) 1.24
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr (2006) 1.24
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis (2009) 1.24
Association of sexual activity with colonization and vaginal acquisition of group B Streptococcus in nonpregnant women. Am J Epidemiol (2002) 1.24
Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol (2004) 1.21
Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol (2004) 1.20
Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex Transm Dis (2005) 1.19
Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis (2005) 1.16
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One (2012) 1.16
Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars. J Bacteriol (2012) 1.13
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J Infect Dis (2007) 1.12
DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol (2003) 1.11
Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol (2003) 1.10
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol (2003) 1.09
Improved methods for typing nontypeable isolates of group B streptococci. Int J Med Microbiol (2002) 1.09
Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol (2005) 1.09
Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis (2009) 1.08
Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. Am J Obstet Gynecol (2003) 1.08
Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis (2006) 1.08
Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque. Sex Transm Dis (2006) 1.07
Quantitative survival of aerobic and anaerobic microorganisms in Port-A-Cul and Copan transport systems. J Clin Microbiol (2008) 1.07
Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol (2005) 1.06
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol (2012) 1.03
DNA macrorestriction analysis of nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J Clin Microbiol (2005) 1.03
Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. J Infect Dis (2011) 1.03
Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis (2009) 1.03
Comparison of API 50 CH strips to whole-chromosomal DNA probes for identification of Lactobacillus species. J Clin Microbiol (2005) 1.02
Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol (2012) 1.01
Racial disparity in risk of preterm birth associated with lower genital tract infection. Paediatr Perinat Epidemiol (2007) 1.01
Association between elevated neutrophil defensin levels and endometritis. J Infect Dis (2002) 1.01
The vaginal inflammatory milieu and the risk of early premature preterm rupture of membranes. Am J Obstet Gynecol (2005) 1.00
Permeability of tritiated water through human cervical and vaginal tissue. J Pharm Sci (2004) 1.00
Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. J Antimicrob Chemother (2004) 0.99
Host immune consequences of asymptomatic Trichomonas vaginalis infection in pregnancy. Am J Obstet Gynecol (2007) 0.99
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis (2006) 0.98
Early pregnancy threshold vaginal pH and Gram stain scores predictive of subsequent preterm birth in asymptomatic women. Am J Obstet Gynecol (2003) 0.97
Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. Am J Obstet Gynecol (2003) 0.97
Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol (2003) 0.97
Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies. J Med Primatol (2004) 0.97
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr (2016) 0.95
Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci (2008) 0.95
Clonal analysis of colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States. J Clin Microbiol (2010) 0.94
Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis (2005) 0.93
Longitudinal reliability of focus glycoprotein G-based type-specific enzyme immunoassays for detection of herpes simplex virus types 1 and 2 in women. J Clin Microbiol (2003) 0.93
Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J (2008) 0.93
Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay. J Clin Microbiol (2003) 0.92
Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis (2013) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. AIDS Res Hum Retroviruses (2013) 0.92
Preformulation and stability in biological fluids of the retrocyclin RC-101, a potential anti-HIV topical microbicide. AIDS Res Ther (2011) 0.91
Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr (2014) 0.91
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. Am J Obstet Gynecol (2002) 0.90
Incidence and epidemiology of Streptococcus pseudoporcinus in the genital tract. J Clin Microbiol (2010) 0.90
Pregnancy-induced changes in immune protection of the genital tract: defining normal. Am J Obstet Gynecol (2013) 0.89
Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex Transm Dis (2003) 0.89
Cervical anti-inflammatory cytokine concentrations among first-trimester pregnant smokers. Am J Obstet Gynecol (2005) 0.88
Rectal colonization by group B Streptococcus as a predictor of vaginal colonization. Am J Obstet Gynecol (2009) 0.88
Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J Womens Health (Larchmt) (2006) 0.87
Adherence of Lactobacillus crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection. J Urol (2006) 0.87
A little bit pregnant: modeling how the accurate detection of pregnancy can improve HIV prevention trials. Am J Epidemiol (2008) 0.87